Dexcom (DXCM)

EBITDA Growth

25.87%

Quarterly · Period ending:

DXCM logo

DXCM EBITDA Growth

Year-over-year change vs the same period a year earlier

Latest reported25.87%
DXCM Quarterly EBITDA YoY % (-78.63% → 25.87%)
High-resolution chart · PNG

DXCM ebitda growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Dexcom EBITDA Growth — Quarterly
Period endingEBITDA Growth
25.8744%
55.1142%
49.6715%
77.1693%
26.1953%
15.5063%
-9.7497%
-19.1141%
17.1374%
71.2737%
74.2824%
54.4737%
69.0129%
41.3793%
303.2407%
57.2848%
-1.4354%
17.0404%
-65.7957%
2.4597%
53.3007%
31.6929%
1.937%
59.7561%
372.8324%
2,922.2222%
177.3891%
28.3478%
-57.9075%
86.3636%
-1,014.8571%
812.6984%
655.4054%
63.4349%
664.5161%
144.0559%
54.0373%
-129.9363%
-167.3913%
63.9798%
-1,510%
-52.4272%
15%
-1,317.8571%
74.359%
0.9615%
1,100%
31.7073%
53.012%
-14.2857%
93.8894%
73.0263%
37.1212%
35.9155%
41.4857%
-23.7886%
-103.9555%
-28.6465%
-21.2683%
5.9945%
40.6347%
40.2512%
-2.5912%
-19.8679%
14.0627%
-74.9101%
24.0284%
17.0826%
-0.5469%
9.3391%
-7.2684%
-22.479%
-17.3674%
-7.5716%
-3.2619%
21.4322%
9.7037%
-12.4202%
12.4494%
-99.0511%
-91.0452%
-78.6316%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.